Core Viewpoint - Zhaoyan New Drug (06127.HK) announced an investment in two Industrial and Commercial Bank of China wealth management products totaling RMB 40 million, bringing the total investment in such products to RMB 410 million as of the announcement date [1] Group 1 - The company has subscribed to two wealth management products from the Industrial and Commercial Bank of China [1] - The total investment amount in these wealth management products is RMB 410 million, which includes the newly subscribed amount and the amount that has not yet been redeemed [1]

Core Viewpoint - Zhaoyan New Drug (06127.HK) announced an investment in two Industrial and Commercial Bank of China wealth management products totaling RMB 40 million, bringing the total investment in such products to RMB 410 million as of the announcement date [1] Group 1 - The company has subscribed to two wealth management products from the Industrial and Commercial Bank of China [1] - The total investment amount in these wealth management products is RMB 410 million, which includes the newly subscribed amount and the amount that has not yet been redeemed [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 董 事 會 謹 此 公 佈，於2025年9月19日（交 易 時 間 後），本 集 團 成 員 公 司 昭 衍（蘇 州） 新 藥 剛 與 工 商 銀 行 訂 立 協 議，認 購 兩 項 工 商 銀 行 理 財 產 品 合 共 人 民 幣40,000,000 元，且 連 同 本 公 告 日 期 仍 未 贖 回 的 該 等 工 商 銀 行 理 財 產 品 合 計 投 資 總 額 為 人 民 幣410,000,000元。 （股 份 代 號：6127） 須予披露交易 認購金融產品 認購金融產品 董 事 會 謹 此 公 佈，於2025年9月19日（交 易 時 間 後），本 集 ...

須予披露交易 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 認購金融產品 認購金融產品 認購金融產品 董 事 會 謹 此 公 佈，於2025年9月19日（交 易 時 間 後），本 集 團 成 員 公 司 剛 認 購 兩 項工商銀行理財產品合共人民幣40,000,000元，且 連 同 於 本 公 告 日 期 仍 未 贖 回的該等工商銀行理財產品合計投資總額為人民幣410,000,000元。 上市規則的涵義 由於根據上市規則第14.07條就第一至第六項工商銀行理財產品計算（無 論 是 單 獨 計 算 或 按 合 併 基 準 計 算）的所有當時適用百分比率均低於5%，因 此 該 等 交 ...

来源：智通财经网 香港联交所最新数据显示，9月15日，FIDELITY FUNDS减持昭衍新药(06127)171.13万股，每股作价 20.4757港元，总金额约为3504.01万港元。减持后最新持股数目1114.34万股，持股比例为9.36%。 ...

香港联交所最新数据显示，9月15日，FIDELITY FUNDS减持昭衍新药（603127）(06127)171.13万股， 每股作价20.4757港元，总金额约为3504.01万港元。减持后最新持股数目1114.34万股，持股比例为 9.36%。 ...

Core Points - On September 17, Zhaoyan New Drug fell by 5.02%, trading at 40.08 CNY per share, with a transaction volume of 1.58 billion CNY and a turnover rate of 6.16%, resulting in a total market capitalization of 30.039 billion CNY [1] - Zhaoyan New Drug Research Center Co., Ltd. specializes in non-clinical safety evaluation services for drugs and preclinical research services, as well as the sale of laboratory animals and related products [1] Shareholder Analysis - Among the top ten circulating shareholders of Zhaoyan New Drug, Huabao Fund's Huabao CSI Medical ETF (512170) increased its holdings by 2.2669 million shares in the second quarter, holding a total of 14.6531 million shares, which accounts for 1.96% of the circulating shares [2] - The estimated floating loss for Huabao CSI Medical ETF today is approximately 31.0646 million CNY [2] - Huabao CSI Medical ETF was established on May 20, 2019, with a latest scale of 26.147 billion CNY, and has achieved a year-to-date return of 21.64% [2]

Core Viewpoint - The company, Zhaoyan New Drug (603127), experienced a significant stock price fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days in September 2025, prompting an investigation into the reasons behind this abnormal trading behavior [1]. Group 1: Production and Operational Status - The company confirmed that its production and operational activities are normal, and there have been no significant changes in the internal or external business environment that would affect the stock price [1]. - There is no undisclosed major information that could impact the stock price [1]. Group 2: Major Events - The company conducted a self-examination and consulted with its controlling shareholders and actual controllers, confirming that there are no major events affecting stock price fluctuations, such as major asset restructuring, share issuance, acquisitions, debt restructuring, asset divestiture, or asset injection [2]. Group 3: Media Reports and Market Rumors - The company has not identified any media reports or market rumors that require clarification or response, nor have there been any other significant events that could substantially impact the stock price [3]. Group 4: Sensitive Information - The company verified that there were no transactions involving the company's stock by its controlling shareholders, actual controllers, directors, supervisors, or senior management during the period of abnormal stock price fluctuations [4].

Core Viewpoint - The company, Zhaoyan New Drug (06127), announced that its A-share stock experienced a cumulative price fluctuation exceeding 20% over three consecutive trading days, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [1]. Group 1: Production and Operational Status - The company confirmed that its production and operational activities are normal, and there have been no significant changes in the internal or external operating environment that would affect the stock price [1]. Group 2: Major Events - A self-examination by the company and inquiries with its controlling shareholders revealed no major events that could impact the stock price, including significant asset restructuring, share issuance, acquisitions, debt restructuring, asset divestiture, or asset injection [2]. Group 3: Media Reports and Market Rumors - The company has not identified any media reports or market rumors that require clarification or response, nor have there been any other significant events that could substantially affect the stock price [3]. Group 4: Other Price-Sensitive Information - The company verified that there were no transactions involving its controlling shareholders, actual controllers, directors, supervisors, or senior management during the period of abnormal stock price fluctuations [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年9月15日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 ...